Article Text

Download PDFPDF
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
  1. Partha Basu, MD, DNB*,
  2. Ajay Mehta, MD,
  3. Minish Jain, MD,
  4. Sudeep Gupta, MD§,
  5. Rajnish V. Nagarkar, MRCS,
  6. Subhashini John, MD and
  7. Robert Petit, PhD#
  1. * Chittaranjan National Cancer Institute, Kolkata;
  2. Central India Cancer Research Institute, Nagpur;
  3. Ruby Hall Clinic, Pune;
  4. § Tata Memorial Hospital, Mumbai;
  5. Curie Manavata Cancer Centre, Nashik; and
  6. Christian Medical College Vellore, Vellore, India; and
  7. # Advaxis, Inc, Princeton, NJ.
  1. Address correspondence and reprint requests to Partha Basu, MD, DNB, Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer (WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France. E-mail: BasuP{at}


Objectives A global unmet medical need exists for effective treatments for persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunotherapies have shown promising survival benefits for patients with advanced forms of cancer. Axalimogene filolisbac (ADXS11-001), a Listeria monocytogenes immunotherapy with a broad effect on the immune system, is under investigation for treatment of human papillomavirus–associated cancers including cervical cancer.

Methods This phase 2 study evaluated the safety and efficacy of ADXS11-001, administered with or without cisplatin, in patients with recurrent/refractory cervical cancer following prior chemotherapy and/or radiotherapy. A total of 109 patients were treated, and 69 were evaluable for tumor response at equal to or more than 3 months postbaseline.

Results Median overall survival (OS) was comparable between treatment groups (ADXS11-001: 8.28 months; 95% confidence interval [CI], 5.85–10.5 months; ADXS11-001 + cisplatin: 8.78 months; 95% CI, 7.4–13.3 months). The 12- and 18-month milestone OS rates were 30.9% versus 38.9%, and 23.6% versus 25.9% for each group, respectively (34.9% and 24.8% combined). Median progression-free survival (6.10 vs 6.08 months) and the overall response rate (17.1% vs 14.7%) were similar for both groups. ADXS11-001 was generally well tolerated; adverse events were predominantly mild to moderate in severity and not related to treatment. More adverse events were reported in the combination group (429 vs 275).

Conclusions These promising safety and efficacy results, including the encouraging 12-month 34.9% combined OS rate, warrant further investigation of ADXS11-001 for treatment of recurrent/refractory cervical cancer.

  • 12-Month survival rate
  • ADXS11-001
  • Cervical cancer
  • Cisplatin
  • Immunotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.